Acetylsalicylic Acid and Salicylic Acid Inhibit SARS-CoV-2 Replication in Precision-Cut Lung Slices

Geiger et al., Vaccines, doi:10.3390/vaccines10101619, Sep 2022

https://c19early.org/geiger.html

In Vitro study showing that aspirin and metabolite salicylic acid inhibit SARS-CoV-2 viral replication in Vero, A549-ACE2, and Huh-7 cells, and in human precision-cut lung slices. Results indicate inhibition of post-entry pathways.

3 preclinical studies support the efficacy of aspirin for COVID-19:

1 In Silico study1

2 In Vitro studies2,3

Important missing comments or errors? Let us know.

1. Eissa et al., Identification of Potential FDA-Approved Inhibitors of SARS-CoV-2 Helicase Through a Multistep In Silico Approach: A Promising Prospect for COVID-19 Treatment, Medicinal Chemistry, doi:10.2174/0115734064318640241112071225.benthamdirect.com, doi.org.

2. Ciszewski et al., Diverse roles of SARS-CoV-2 Spike and Nucleocapsid proteins in EndMT stimulation through the TGF-β-MRTF axis inhibited by aspirin, Cell Communication and Signaling, doi:10.1186/s12964-024-01665-z.biomedcentral.com, doi.org.

3. Geiger et al., Acetylsalicylic Acid and Salicylic Acid Inhibit SARS-CoV-2 Replication in Precision-Cut Lung Slices, Vaccines, doi:10.3390/vaccines10101619.mdpi.com, doi.org.

Geiger et al., 27 Sep 2022, peer-reviewed, 11 authors. Contact: jochen.bodem@uni-wuerzburg.de (corresponding author).

In Vitro studies are an important part of preclinical research, however results may be very different in vivo.

This Paper Aspirin All

Acetylsalicylic Acid and Salicylic Acid Inhibit SARS-CoV-2 Replication in Precision-Cut Lung Slices

Nina Geiger, Eva-Maria König, Heike Oberwinkler, Valeria Roll, Viktoria Diesendorf, Sofie Fähr, Helena Obernolte, Katherina Sewald, Sabine Wronski, Maria Steinke, Jochen Bodem

Vaccines, doi:10.3390/vaccines10101619

Aspirin, with its active compound acetylsalicylic acid (ASA), shows antiviral activity against rhino-and influenza viruses at high concentrations. We sought to investigate whether ASA and its metabolite salicylic acid (SA) inhibit SARS-CoV-2 since it might use similar pathways to influenza viruses. The compound-treated cells were infected with SARS-CoV-2. Viral replication was analysed by RTqPCR. The compounds suppressed SARS-CoV-2 replication in cell culture cells and a patient-near replication system using human precision-cut lung slices by two orders of magnitude. While the compounds did not interfere with viral entry, it led to lower viral RNA expression after 24 h, indicating that post-entry pathways were inhibited by the compounds.

Funding: Bayer Vital GmbH funded a part of this study. This publication was supported by the Open Access Publication Fund of the University of Wuerzburg. Conflicts of Interest: Bayer Vital GmbH funded a part of this study but had no role in the design of the study; in the collection, analysis or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

Avota, Bodem, Chithelen, Mandasari, Beyersdorf et al., The Manifold Roles of Sphingolipids in Viral Infections, Front. Physiol, doi:10.3389/fphys.2021.715527

Chow, Khanna, Kethireddy, Yamane, Levine et al., Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients with Coronavirus Disease, Anesth. Analg, doi:10.1213/ANE.0000000000005292

Di Bella, Luzzati, Principe, Zerbato, Meroni et al., Aspirin and Infection: A Narrative Review, Biomedicines, doi:10.3390/biomedicines10020263

Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect. Dis, doi:10.1016/S1473-3099(20)30120-1

Geiger, Kersting, Schlegel, Stelz, Fahr et al., The Acid Ceramidase Is a SARS-CoV-2 Host Factor, Cells, doi:10.3390/cells11162532

Glatthaar-Saalmuller, Mair, Saalmuller, Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study, Influenza Respir. Viruses, doi:10.1111/irv.12421

Goldman, Lye, Hui, Marks, Bruno et al., Remdesivir for 5 or 10 Days in Patients with Severe COVID-19, N. Engl. J. Med, doi:10.1056/NEJMoa2015301

Hoffmann, Mosbauer, Hofmann-Winkler, Kaul, Kleine-Weber et al., Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2, Nature

Jancso, Cserepes, Gasz, Benko, Ferencz et al., Effect of acetylsalicylic acid on nuclear factor-kappaB activation and on late preconditioning against infarction in the myocardium, J. Cardiovasc. Pharm, doi:10.1097/01.fjc.0000175240.64444.68

Khoo, Fitzgerald, Fletcher, Ewings, Jaki et al., Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: A Phase I, open-label, dose-escalating, randomized controlled study, J. Antimicrob. Chemother, doi:10.1093/jac/dkab318

Kumar, Xin, Liang, Ly, Liang, NF-kappaB signaling differentially regulates influenza virus RNA synthesis, J. Virol, doi:10.1128/JVI.00909-08

Liu, Han, Blair, Kenst, Qin et al., SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro, Front. Cell. Infect. Microbiol, doi:10.3389/fcimb.2021.701278

Liu, Huang, Li, Zhou, Liang et al., Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19, Medicine, doi:10.1097/MD.0000000000024544

Maisonnasse, Guedj, Contreras, Behillil, Solas et al., Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates, Nature, doi:10.1038/s41586-020-2558-4

Mazur, Wurzer, Ehrhardt, Pleschka, Puthavathana et al., Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity, Cell Microbiol, doi:10.1111/j.1462-5822.2007.00902.x

Neuhaus, Danov, Konzok, Obernolte, Dehmel et al., Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices, J. Vis. Exp, doi:10.3791/57042

Nilsson-Payant, Uhl, Grimont, Doane, Cohen et al., The NF-kappaB Transcriptional Footprint Is Essential for SARS-CoV-2 Replication, J. Virol, doi:10.1128/JVI.01257-21

Oskotsky, Maric, Tang, Oskotsky, Wong et al., Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants, JAMA Netw. Open, doi:10.1001/jamanetworkopen.2021.33090

Perlman, Masters, Coronaviridae: The Viruses and Their Replication, Fields Virology

Schmidt, Lareau, Keshishian, Ganskih, Schneider et al., The SARS-CoV-2 RNA-protein interactome in infected human cells, Nat. Microbiol, doi:10.1038/s41564-020-00846-z

Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0

Zimniak, Kirschner, Hilpert, Geiger, Danov et al., The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue, Sci. Rep, doi:10.1038/s41598-021-85049-0

DOI record: { "DOI": "10.3390/vaccines10101619", "ISSN": [ "2076-393X" ], "URL": "http://dx.doi.org/10.3390/vaccines10101619", "abstract": "Aspirin, with its active compound acetylsalicylic acid (ASA), shows antiviral activity against rhino- and influenza viruses at high concentrations. We sought to investigate whether ASA and its metabolite salicylic acid (SA) inhibit SARS-CoV-2 since it might use similar pathways to influenza viruses. The compound-treated cells were infected with SARS-CoV-2. Viral replication was analysed by RTqPCR. The compounds suppressed SARS-CoV-2 replication in cell culture cells and a patient-near replication system using human precision-cut lung slices by two orders of magnitude. While the compounds did not interfere with viral entry, it led to lower viral RNA expression after 24 h, indicating that post-entry pathways were inhibited by the compounds.", "alternative-id": [ "vaccines10101619" ], "author": [ { "ORCID": "http://orcid.org/0000-0002-2974-6290", "affiliation": [], "authenticated-orcid": false, "family": "Geiger", "given": "Nina", "sequence": "first" }, { "affiliation": [], "family": "König", "given": "Eva-Maria", "sequence": "additional" }, { "affiliation": [], "family": "Oberwinkler", "given": "Heike", "sequence": "additional" }, { "affiliation": [], "family": "Roll", "given": "Valeria", "sequence": "additional" }, { "affiliation": [], "family": "Diesendorf", "given": "Viktoria", "sequence": "additional" }, { "affiliation": [], "family": "Fähr", "given": "Sofie", "sequence": "additional" }, { "affiliation": [], "family": "Obernolte", "given": "Helena", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-7804-4527", "affiliation": [], "authenticated-orcid": false, "family": "Sewald", "given": "Katherina", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-2332-226X", "affiliation": [], "authenticated-orcid": false, "family": "Wronski", "given": "Sabine", "sequence": "additional" }, { "affiliation": [], "family": "Steinke", "given": "Maria", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-1908-4091", "affiliation": [], "authenticated-orcid": false, "family": "Bodem", "given": "Jochen", "sequence": "additional" } ], "container-title": "Vaccines", "container-title-short": "Vaccines", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2022, 9, 29 ] ], "date-time": "2022-09-29T05:23:16Z", "timestamp": 1664428996000 }, "deposited": { "date-parts": [ [ 2022, 10, 14 ] ], "date-time": "2022-10-14T08:00:33Z", "timestamp": 1665734433000 }, "funder": [ { "award": [ "-" ], "name": "Bayer Vital GmbH" } ], "indexed": { "date-parts": [ [ 2022, 10, 14 ] ], "date-time": "2022-10-14T08:42:35Z", "timestamp": 1665736955962 }, "is-referenced-by-count": 0, "issue": "10", "issued": { "date-parts": [ [ 2022, 9, 27 ] ] }, "journal-issue": { "issue": "10", "published-online": { "date-parts": [ [ 2022, 10 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 9, 27 ] ], "date-time": "2022-09-27T00:00:00Z", "timestamp": 1664236800000 } } ], "link": [ { "URL": "https://www.mdpi.com/2076-393X/10/10/1619/pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "1968", "original-title": [], "page": "1619", "prefix": "10.3390", "published": { "date-parts": [ [ 2022, 9, 27 ] ] }, "published-online": { "date-parts": [ [ 2022, 9, 27 ] ] }, "publisher": "MDPI AG", "reference": [ { "DOI": "10.1016/S1473-3099(20)30120-1", "doi-asserted-by": "publisher", "key": "ref1" }, { "DOI": "10.1093/jac/dkab318", "doi-asserted-by": "publisher", "key": "ref2" }, { "DOI": "10.1038/s41422-020-0282-0", "doi-asserted-by": "publisher", "key": "ref3" }, { "DOI": "10.1056/NEJMoa2015301", "doi-asserted-by": "publisher", "key": "ref4" }, { "DOI": "10.1038/s41598-021-85049-0", "doi-asserted-by": "publisher", "key": "ref5" }, { "DOI": "10.1001/jamanetworkopen.2021.33090", "doi-asserted-by": "publisher", "key": "ref6" }, { "DOI": "10.1038/s41586-020-2575-3", "doi-asserted-by": "publisher", "key": "ref7" }, { "DOI": "10.3390/cells11162532", "doi-asserted-by": "publisher", "key": "ref8" }, { "DOI": "10.1111/irv.12421", "doi-asserted-by": "publisher", "key": "ref9" }, { "DOI": "10.3390/biomedicines10020263", "doi-asserted-by": "publisher", "key": "ref10" }, { "DOI": "10.1097/MD.0000000000024544", "doi-asserted-by": "publisher", "key": "ref11" }, { "DOI": "10.1213/ANE.0000000000005292", "doi-asserted-by": "publisher", "key": "ref12" }, { "DOI": "10.3389/fcimb.2021.701278", "doi-asserted-by": "publisher", "key": "ref13" }, { "DOI": "10.3389/fphys.2021.715527", "doi-asserted-by": "publisher", "key": "ref14" }, { "article-title": "Coronaviridae: The Viruses and Their Replication", "author": "Perlman", "first-page": "410", "key": "ref15", "series-title": "Fields Virology", "volume": "Volume 1", "year": "2021" }, { "DOI": "10.1038/s41564-020-00846-z", "doi-asserted-by": "publisher", "key": "ref16" }, { "DOI": "10.3791/57042", "doi-asserted-by": "publisher", "key": "ref17" }, { "DOI": "10.1038/s41586-020-2558-4", "doi-asserted-by": "publisher", "key": "ref18" }, { "DOI": "10.1128/JVI.00909-08", "doi-asserted-by": "publisher", "key": "ref19" }, { "DOI": "10.1097/01.fjc.0000175240.64444.68", "doi-asserted-by": "publisher", "key": "ref20" }, { "DOI": "10.1111/j.1462-5822.2007.00902.x", "doi-asserted-by": "publisher", "key": "ref21" }, { "DOI": "10.1128/JVI.01257-21", "doi-asserted-by": "publisher", "key": "ref22" } ], "reference-count": 22, "references-count": 22, "relation": {}, "resource": { "primary": { "URL": "https://www.mdpi.com/2076-393X/10/10/1619" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Pharmacology (medical)", "Infectious Diseases", "Drug Discovery", "Pharmacology", "Immunology" ], "subtitle": [], "title": "Acetylsalicylic Acid and Salicylic Acid Inhibit SARS-CoV-2 Replication in Precision-Cut Lung Slices", "type": "journal-article", "volume": "10" }

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0